MetaCap

Cencora Inc. (COR)

NYSE: CORHealth CareOther PharmaceuticalsUSD

339.09-2.16 (-0.63%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

COR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$64.71B
EPS (TTM)
$17.95
Dividend yield
0.71% ($2.40)
Ex-dividend date
Nov 13, 2026
52-week range
244.82 – 377.54
Day range
337.88 – 348.57
Volume / Avg
1.23M / 1.29M
Beta
—

52-week range

$244.82$377.54

COR stock today

Shares of Cencora (COR) finished lower on Nov 20 at $339.09, a drop of 0.63% or $2.16 per share, versus the S&P 500's 3.70% decline. At this level, COR sits in the middle of its 52-week range of $244.82 to $377.54: 10.2% below the high, set on Nov 25, 2025 and 38.5% above the low. COR is up 0.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 7.3%.

At 18.9x trailing earnings, Cencora trades below the peer-group median of 27.6x. Its forward P/E of 15.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Cencora pays an annual dividend of $2.40 per share, a 0.71% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Cencora

Company profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.

Industry
Other Pharmaceuticals
CEO
Dr. Robert P. Mauch Ph.D., PharmD
Headquarters
Conshohocken, PA
Employees
47,000

Financial highlights

Full financials

In fiscal 2025, Cencora generated $321.33 billion in revenue, up 9.3% from fiscal 2024, its 13th consecutive year of revenue growth. Net income was $1.55 billion (+3.0% year over year), for a net margin of 0.5% versus a median of 0.7% in the prior 5 years. Gross margin was 3.6% (up from 3.4%) and operating margin 0.8%.

Cencora annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$321.33B$293.96B$262.17B$238.59B$213.99B
Growth+9.31%+12.12%+9.89%+11.50%+12.69%
Net income$1.55B$1.51B$1.75B$1.70B$1.54B
EPS (diluted)$7.96$7.53$8.53$8.04$7.39

Analyst forecast

Forecast

Consensus (14 analysts)

buy

Avg. price target

$382.42+12.78%

  • Strong buy 3
  • Buy 7
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $330.00High $414.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$3.84 vs $4.56
Surprise
-15.79%

Dividends

Dividend history
Annual dividend
$2.40
Last payment
$0.66
Ex-dividend date
Nov 13, 2026

COR news

All COR news

Cencora peers

Health Care sector
COR peer companies
CompanyPrice% ChgMarket capCompare
CAHCardinal Health Inc.272.81+0.17%$63.06Bvs COR
MCKMcKesson Corporation1,069.43+0.68%$123.47Bvs COR
HLFHerbalife Ltd.15.53-0.26%$1.63Bvs COR
NUSNu Skin Enterprises Inc.3.80+0.80%$184.98Mvs COR
ESYNEnerSyn Global Inc.1.11-0.89%$37.44Mvs COR
COSMCosmos Health Inc.2.81-2.09%$14.14Mvs COR
MEDSDataMeds AI Inc.1.34+84.14%$7.67Mvs COR
HKPDCellyan Biotechnology Co. Ltd Class A1.38+2.60%$3.40Mvs COR

Indexes, lists and sector

Cencora stock FAQ

What is Cencora's stock price today?

COR last traded at $339.09 as of Nov 20, 4:00 PM EST, down 0.63% on the day. Prices are delayed at least 15 minutes.

Does Cencora pay a dividend?

Yes. Cencora pays $2.40 per share annually, a 0.71% yield. The most recent dividend of $0.66 had an ex-dividend date of Nov 13, 2026.

What is COR's P/E ratio?

COR trades at a trailing P/E ratio of 18.89 and a forward P/E of 15.60, compared with a median of 27.6 for its closest peers.

Is Cencora in the S&P 500?

Yes. Cencora (COR) is a constituent of the S&P 500 index.

Who is Cencora's CEO?

Dr. Robert P. Mauch Ph.D., PharmD is the chief executive officer of Cencora Inc., which has about 47,000 employees.

Has COR ever split its stock?

Yes. The most recent COR stock split was a 2-for-1 split on Jun 16, 2009, one of 3 splits on record.

What is the COR 52-week high?

The 52-week high for COR is $377.54 and the 52-week low is $244.82. The stock is currently 10.2% below its high.

Compare COR